{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:29:58Z","timestamp":1787243398870,"version":"build-2736575974"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Endocrinol"],"DOI":"10.1038\/s41574-026-01296-z","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:53:06Z","timestamp":1787237586000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Diagnosis of hypochondroplasia: international Delphi consensus recommendations"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4890-0262","authenticated-orcid":false,"given":"Andrew","family":"Dauber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moira S.","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1242-5626","authenticated-orcid":false,"given":"Julie","family":"Hoover-Fong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svein Otto","family":"Fredwall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moeenaldeen","family":"AlSayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio","family":"Boero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alistair D.","family":"Calder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2839-9856","authenticated-orcid":false,"given":"Val\u00e9rie","family":"Cormier-Daire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3311-2220","authenticated-orcid":false,"given":"Virginia","family":"Fano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuo","family":"Kubota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Kunkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Llerena Junior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7183-5238","authenticated-orcid":false,"given":"Mohamad","family":"Maghnie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9871-4578","authenticated-orcid":false,"given":"Geert","family":"Mortier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyuki","family":"Namba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8991-5036","authenticated-orcid":false,"given":"Amaka C.","family":"Offiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keita","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9rgio B.","family":"Sousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5105-8427","authenticated-orcid":false,"given":"Ravi","family":"Savarirayan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,20]]},"reference":[{"key":"1296_CR1","unstructured":"Bober, M. B. et al. Hypochondroplasia. In GeneReviews (eds Adam, M. P. et al.) (Univ. of Washington, 1993)."},{"key":"1296_CR2","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1055\/a-1988-9734","volume":"131","author":"HY Kim","year":"2023","unstructured":"Kim, H. Y., Lee, Y. A., Shin, C. H., Cho, T.-J. & Ko, J. M. Clinical manifestations and outcomes of 20 Korean hypochondroplasia patients with the FGFR3 N540K variant. Exp. Clin. Endocrinol. Diabetes 131, 123\u2013131 (2023).","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"key":"1296_CR3","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1002\/ajmg.a.35564","volume":"158A","author":"S Song","year":"2012","unstructured":"Song, S. et al. New proposed clinico-radiologic and molecular criteria in hypochondroplasia: FGFR3 gene mutations are not the only cause of hypochondroplasia. Am. J. Med. Genet. A 158A, 2456\u20132462 (2012).","journal-title":"Am. J. Med. Genet. A"},{"key":"1296_CR4","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s002470000398","volume":"31","author":"C Prinster","year":"2001","unstructured":"Prinster, C. et al. Diagnosis of hypochondroplasia: the role of radiological interpretation. Pediatr. Radiol. 31, 203\u2013208 (2001).","journal-title":"Pediatr. Radiol."},{"key":"1296_CR5","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1111\/ped.12511","volume":"56","author":"K Hasegawa","year":"2014","unstructured":"Hasegawa, K. & Tanaka, H. Children with short-limbed short stature in pediatric endocrinological services in Japan. Pediatr. Int. 56, 809\u2013812 (2014).","journal-title":"Pediatr. Int."},{"key":"1296_CR6","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1002\/ajmg.a.64266","volume":"200","author":"MS Cheung","year":"2026","unstructured":"Cheung, M. S., Lanzafame, R., Low, K. J. & Cole, T. J. The head circumference height index (HCH-I) to quantify relative macrocephaly and aid identification of hypochondroplasia in children. Am. J. Med. Genet. A 200, 353\u2013359 (2026).","journal-title":"Am. J. Med. Genet. A"},{"key":"1296_CR7","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1080\/03014460500268481","volume":"32","author":"V Fano","year":"2005","unstructured":"Fano, V. et al. High specificity of head circumference to recognize N540K mutation in hypochondroplasia. Ann. Hum. Biol. 32, 782\u2013788 (2005).","journal-title":"Ann. Hum. Biol."},{"key":"1296_CR8","first-page":"1279","volume":"31","author":"MA Arenas","year":"2018","unstructured":"Arenas, M. A., Del Pino, M. & Fano, V. FGFR3-related hypochondroplasia: longitudinal growth in 57 children with the p.Asn540Lys mutation. J. Pediatr. Endocrinol. Metab. 31, 1279\u20131284 (2018).","journal-title":"J. Pediatr. Endocrinol. Metab."},{"key":"1296_CR9","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/ajmg.a.63431","volume":"194","author":"MS Cheung","year":"2024","unstructured":"Cheung, M. S. et al. Growth reference charts for children with hypochondroplasia. Am. J. Med. Genet. A 194, 243\u2013252 (2024).","journal-title":"Am. J. Med. Genet. A"},{"key":"1296_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-025-04069-5","volume":"20","author":"G Baujat","year":"2025","unstructured":"Baujat, G., Hamandjian, M.-A., Jannot, A.-S., Karam, P. & Cormier-Daire, V. Achondroplasia and hypochondroplasia in France: a nationwide epidemiological analysis. Orphanet J. Rare Dis. 20, 555 (2025).","journal-title":"Orphanet J. Rare Dis."},{"key":"1296_CR11","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1302\/0301-620X.63B4.7298674","volume":"63-B","author":"R Wynne-Davies","year":"1981","unstructured":"Wynne-Davies, R., Walsh, W. & Gormley, J. Achondroplasia and hypochondroplasia. Clinical variation and spinal stenosis. J. Bone Jt Surg. Br. 63-B, 508\u2013515 (1981).","journal-title":"J. Bone Jt Surg. Br."},{"key":"1296_CR12","doi-asserted-by":"publisher","first-page":"4321","DOI":"10.3390\/ijms22094321","volume":"22","author":"A Guasto","year":"2021","unstructured":"Guasto, A. & Cormier-Daire, V. Signaling pathways in bone development and their related skeletal dysplasia. Int. J. Mol. Sci. 22, 4321 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"1296_CR13","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1002\/humu.21636","volume":"33","author":"S Foldynova-Trantirkova","year":"2012","unstructured":"Foldynova-Trantirkova, S., Wilcox, W. R. & Krejci, P. Sixteen years and counting: the current understanding of fibroblast growth factor receptor 3 (FGFR3) signaling in skeletal dysplasias. Hum. Mutat. 33, 29\u201341 (2012).","journal-title":"Hum. Mutat."},{"key":"1296_CR14","doi-asserted-by":"publisher","first-page":"E355","DOI":"10.1210\/jc.2014-2814","volume":"100","author":"RC Olney","year":"2015","unstructured":"Olney, R. C. et al. C-Type natriuretic peptide plasma levels are elevated in subjects with achondroplasia, hypochondroplasia, and thanatophoric dysplasia. J. Clin. Endocrinol. Metab. 100, E355\u2013E359 (2015).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1296_CR15","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1148\/133.1.95","volume":"133","author":"BD Hall","year":"1979","unstructured":"Hall, B. D. & Spranger, J. Hypochondroplasia: clinical and radiological aspects in 39 cases. Radiology 133, 95\u2013100 (1979).","journal-title":"Radiology"},{"key":"1296_CR16","volume":"123","author":"SS Chiaramonte","year":"2025","unstructured":"Chiaramonte, S. S., Del Pino, M. & Fano, V. Prevalence of low birth weight, short length, and body disproportion at birth in patients with skeletal dysplasias: a retrospective study. Arch. Argent. Pediatr. 123, e202510663 (2025).","journal-title":"Arch. Argent. Pediatr."},{"key":"1296_CR17","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1002\/mgg3.96","volume":"2","author":"Y Xue","year":"2014","unstructured":"Xue, Y. et al. FGFR3 mutation frequency in 324 cases from the International Skeletal Dysplasia Registry. Mol. Genet. Genomic Med. 2, 497\u2013503 (2014).","journal-title":"Mol. Genet. Genomic Med."},{"key":"1296_CR18","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1111\/j.1399-0004.2008.01123.x","volume":"75","author":"M Almeida","year":"2009","unstructured":"Almeida, M. et al. Clinical and molecular diagnosis of the skeletal dysplasias associated with mutations in the gene encoding Fibroblast Growth Factor Receptor 3 (FGFR3) in Portugal. Clin. Genet. 75, 150\u2013156 (2009).","journal-title":"Clin. Genet."},{"key":"1296_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/mgg3.70151","volume":"13","author":"EM Oehrlein","year":"2025","unstructured":"Oehrlein, E. M. et al. Living with hypochondroplasia: a qualitative exploration of children\u2019s and caregivers\u2019 experiences, challenges, and unmet needs. Mol. Genet. Genomic Med. 13, e70151 (2025).","journal-title":"Mol. Genet. Genomic Med."},{"key":"1296_CR20","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1002\/ajmg.a.35642","volume":"158A","author":"T Linnankivi","year":"2012","unstructured":"Linnankivi, T., M\u00e4kitie, O., Valanne, L. & Toiviainen-Salo, S. Neuroimaging and neurological findings in patients with hypochondroplasia and FGFR3 N540K mutation. Am. J. Med. Genet. A 158A, 3119\u20133125 (2012).","journal-title":"Am. J. Med. Genet. A"},{"key":"1296_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102591","volume":"71","author":"A Dauber","year":"2024","unstructured":"Dauber, A. et al. Vosoritide treatment for children with hypochondroplasia: a phase 2 trial. EClinicalMedicine 71, 102591 (2024).","journal-title":"EClinicalMedicine"},{"key":"1296_CR22","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1093\/jbmr\/zjaf088","volume":"40","author":"B Demuynck","year":"2025","unstructured":"Demuynck, B. et al. Infigratinib low dose therapy is an effective strategy to treat hypochondroplasia. J. Bone Miner. Res. 40, 1255\u20131264 (2025).","journal-title":"J. Bone Miner. Res."},{"key":"1296_CR23","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1159\/000542102","volume":"99","author":"D Galetaki","year":"2024","unstructured":"Galetaki, D. et al. Phase 2 trial of vosoritide use in patients with hypochondroplasia: a pharmacokinetic\/pharmacodynamic analysis. Horm. Res. Paediatr. 99, 131\u2013137 (2024).","journal-title":"Horm. Res. Paediatr."},{"key":"1296_CR24","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/ajmg.a.61912","volume":"185","author":"AH Sabir","year":"2021","unstructured":"Sabir, A. H. et al. Earlier detection of hypochondroplasia: a large single-center UK case series and systematic review. Am. J. Med. Genet. A 185, 73\u201382 (2021).","journal-title":"Am. J. Med. Genet. A"},{"key":"1296_CR25","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s00247-015-3518-2","volume":"46","author":"T Saito","year":"2016","unstructured":"Saito, T. et al. Criteria for radiologic diagnosis of hypochondroplasia in neonates. Pediatr. Radiol. 46, 513\u2013518 (2016).","journal-title":"Pediatr. Radiol."},{"key":"1296_CR26","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0022-3476(98)70186-6","volume":"133","author":"U Ramaswami","year":"1998","unstructured":"Ramaswami, U., Rumsby, G., Hindmarsh, P. C. & Brook, C. G. D. Genotype and phenotype in hypochondroplasia. J. Pediatr. 133, 99\u2013102 (1998).","journal-title":"J. Pediatr."},{"key":"1296_CR27","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1002\/ajmg.a.37776","volume":"170","author":"SC Shelmerdine","year":"2016","unstructured":"Shelmerdine, S. C., Brittain, H., Arthurs, O. J. & Calder, A. D. Achondroplasia: really rhizomelic? Am. J. Med. Genet. A 170, 2039\u20132043 (2016).","journal-title":"Am. J. Med. Genet. A"},{"key":"1296_CR28","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1515\/jpem-2020-0679","volume":"34","author":"T Xu","year":"2021","unstructured":"Xu, T. et al. An intronic variant disrupts mRNA splicing and causes FGFR3-related skeletal dysplasia. J. Pediatr. Endocrinol. Metab. 34, 1323\u20131328 (2021).","journal-title":"J. Pediatr. Endocrinol. Metab."},{"key":"1296_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-025-03936-5","volume":"20","author":"S Wei","year":"2025","unstructured":"Wei, S. et al. Identification of NPR2 gene mutations affecting chondrocyte differentiation in short stature through JAK2\u2013STAT5. Orphanet J. Rare Dis. 20, 392 (2025).","journal-title":"Orphanet J. Rare Dis."},{"key":"1296_CR30","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1111\/apa.70029","volume":"114","author":"S Zhan","year":"2025","unstructured":"Zhan, S. et al. Clinical features of seven COL2A1 variations in Chinese children with type II collagen disorders. Acta Paediatr. 114, 1720\u20131730 (2025).","journal-title":"Acta Paediatr."},{"key":"1296_CR31","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1097\/MOP.0000000000001481","volume":"37","author":"R Nicolae","year":"2025","unstructured":"Nicolae, R., Navardauskaite, R. & Jee, Y. H. Genetics of short stature. Curr. Opin. Pediatr. 37, 380\u2013385 (2025).","journal-title":"Curr. Opin. Pediatr."},{"key":"1296_CR32","doi-asserted-by":"publisher","first-page":"2788","DOI":"10.1080\/14767058.2020.1802715","volume":"35","author":"AC Jelin","year":"2022","unstructured":"Jelin, A. C. et al. Molecular testing strategies in the evaluation of fetal skeletal dysplasia. J. Matern. Fetal Neonatal Med. 35, 2788\u20132794 (2022).","journal-title":"J. Matern. Fetal Neonatal Med."},{"key":"1296_CR33","doi-asserted-by":"publisher","first-page":"20221025","DOI":"10.1259\/bjr.20221025","volume":"96","author":"G Nishimura","year":"2023","unstructured":"Nishimura, G. et al. Prenatal diagnosis of bone dysplasias. Br. J. Radiol. 96, 20221025 (2023).","journal-title":"Br. J. Radiol."},{"key":"1296_CR34","doi-asserted-by":"publisher","first-page":"2606517","DOI":"10.1080\/07853890.2025.2606517","volume":"58","author":"L Wang","year":"2026","unstructured":"Wang, L. et al. Genetic analysis of fetal skeletal dysplasia via whole exome sequencing and non-invasive prenatal diagnosis. Ann. Med. 58, 2606517 (2026).","journal-title":"Ann. Med."},{"key":"1296_CR35","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1038\/s41372-025-02343-9","volume":"45","author":"E Kalimi","year":"2025","unstructured":"Kalimi, E. et al. The role of genetic testing in small for gestational age infants. J. Perinatol. 45, 1183\u20131190 (2025).","journal-title":"J. Perinatol."},{"key":"1296_CR36","unstructured":"Online Mendelian inheritance in man. Fibroblast growth factor receptor 3; FGFR3 (MIM 134934). OMIM https:\/\/omim.org\/entry\/134934 (2026)."},{"key":"1296_CR37","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1086\/316892","volume":"67","author":"GA Bellus","year":"2000","unstructured":"Bellus, G. A. et al. Distinct missense mutations of the FGFR3 Lys650 codon modulate receptor kinase activation and the severity of the skeletal dysplasia phenotype. Am. J. Hum. Genet. 67, 1411\u20131421 (2000).","journal-title":"Am. J. Hum. Genet."},{"key":"1296_CR38","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards, S. et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 17, 405\u2013424 (2015).","journal-title":"Genet. Med."},{"key":"1296_CR39","doi-asserted-by":"publisher","first-page":"225","DOI":"10.3390\/genes15020225","volume":"15","author":"ZG Ouedraogo","year":"2024","unstructured":"Ouedraogo, Z. G. et al. Relevance of extending FGFR3 gene analysis in osteochondrodysplasia to non-coding sequences: a case report. Genes 15, 225 (2024).","journal-title":"Genes"},{"key":"1296_CR40","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1038\/sj.ejhg.5201700","volume":"14","author":"S Heuertz","year":"2006","unstructured":"Heuertz, S. et al. Novel FGFR3 mutations creating cysteine residues in the extracellular domain of the receptor cause achondroplasia or severe forms of hypochondroplasia. Eur. J. Hum. Genet. 14, 1240\u20131247 (2006).","journal-title":"Eur. J. Hum. Genet."},{"key":"1296_CR41","doi-asserted-by":"publisher","DOI":"10.1530\/EC-22-0214","volume":"11","author":"NLM Andrade","year":"2022","unstructured":"Andrade, N. L. M. et al. Diagnostic yield of a multigene sequencing approach in children classified as idiopathic short stature. Endocr. Connect. 11, e220214 (2022).","journal-title":"Endocr. Connect."},{"key":"1296_CR42","doi-asserted-by":"publisher","first-page":"1102968","DOI":"10.3389\/fendo.2022.1102968","volume":"13","author":"L Plachy","year":"2023","unstructured":"Plachy, L. et al. Isolated growth hormone deficiency in children with vertically transmitted short stature: what do the genes tell us? Front. Endocrinol. 13, 1102968 (2023).","journal-title":"Front. Endocrinol."},{"key":"1296_CR43","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.63646","volume":"194","author":"G MacCarrick","year":"2024","unstructured":"MacCarrick, G. et al. Clinical utility of comprehensive gene panel testing for common and rare causes of skeletal dysplasia and other skeletal disorders: results from the largest cohort to date. Am. J. Med. Genet. A 194, e63646 (2024).","journal-title":"Am. J. Med. Genet. A"},{"key":"1296_CR44","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1055\/s-0039-1695056","volume":"9","author":"R Ramos Mej\u00eda","year":"2020","unstructured":"Ramos Mej\u00eda, R. et al. Clinical and radiologic evaluation of an individual with hypochondroplasia and a novel FGFR3 mutation. J. Pediatr. Genet. 9, 48\u201352 (2020).","journal-title":"J. Pediatr. Genet."},{"key":"1296_CR45","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.tjog.2013.10.023","volume":"52","author":"C-P Chen","year":"2013","unstructured":"Chen, C.-P. et al. Detection of a de novo Y278C mutation in FGFR3 in a pregnancy with severe fetal hypochondroplasia: prenatal diagnosis and literature review. Taiwan J. Obstet. Gynecol. 52, 580\u2013585 (2013).","journal-title":"Taiwan J. Obstet. Gynecol."},{"key":"1296_CR46","first-page":"932","volume":"15","author":"F Li","year":"2013","unstructured":"Li, F. et al. Clinical analysis and genetic diagnosis of short-limb inherited short stature diseases in children. Zhongguo Dang Dai Er Ke Za Zhi 15, 932\u2013936 (2013).","journal-title":"Zhongguo Dang Dai Er Ke Za Zhi"},{"key":"1296_CR47","first-page":"19241","volume":"8","author":"R Zhao","year":"2015","unstructured":"Zhao, R., Ruan, Y. & Wang, X. Whole-exome sequencing and whole genome re-sequencing for prenatal diagnosis of achondroplasia. Int. J. Clin. Exp. Med. 8, 19241\u201319249 (2015).","journal-title":"Int. J. Clin. Exp. Med."},{"key":"1296_CR48","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1038\/gim.2018.30","volume":"20","author":"N Chandler","year":"2018","unstructured":"Chandler, N. et al. Rapid prenatal diagnosis using targeted exome sequencing: a cohort study to assess feasibility and potential impact on prenatal counseling and pregnancy management. Genet. Med. 20, 1430\u20131437 (2018).","journal-title":"Genet. Med."},{"key":"1296_CR49","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/sj.ejhg.5201931","volume":"16","author":"MJ Friez","year":"2008","unstructured":"Friez, M. J. & Wilson, J. A. P. Novel FGFR3 mutations in exon 7 and implications for expanded screening of achondroplasia and hypochondroplasia: a response to Heuertz et al. Eur. J. Hum. Genet. 16, 277\u2013278 (2008).","journal-title":"Eur. J. Hum. Genet."},{"key":"1296_CR50","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1002\/ajmg.a.34424","volume":"158A","author":"T Saito","year":"2012","unstructured":"Saito, T. et al. Radiological clues to the early diagnosis of hypochondroplasia in the neonatal period: report of two patients. Am. J. Med. Genet. A 158A, 630\u2013634 (2012).","journal-title":"Am. J. Med. Genet. A"},{"key":"1296_CR51","doi-asserted-by":"publisher","first-page":"428","DOI":"10.3390\/endocrines3030034","volume":"3","author":"T Ishii","year":"2022","unstructured":"Ishii, T. et al. Molecular basis for hypochondroplasia in Japan. Endocrines 3, 428\u2013432 (2022).","journal-title":"Endocrines"},{"key":"1296_CR52","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1297\/cpe.25.103","volume":"25","author":"K Nagahara","year":"2016","unstructured":"Nagahara, K. et al. A Japanese familial case of hypochondroplasia with a novel mutation in FGFR3. Clin. Pediatr. Endocrinol. 25, 103\u2013106 (2016).","journal-title":"Clin. Pediatr. Endocrinol."},{"key":"1296_CR53","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1152\/physiolgenomics.2000.2.1.9","volume":"2","author":"A Winterpacht","year":"2000","unstructured":"Winterpacht, A. et al. A novel mutation in FGFR-3 disrupts a putative N-glycosylation site and results in hypochondroplasia. Physiol. Genomics 2, 9\u201312 (2000).","journal-title":"Physiol. Genomics"},{"key":"1296_CR54","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1002\/ajmg.a.38141","volume":"173","author":"NL Couser","year":"2017","unstructured":"Couser, N. L. et al. Mild achondroplasia\/hypochondroplasia with acanthosis nigricans, normal development, and a p.Ser348Cys FGFR3 mutation. Am. J. Med. Genet. A 173, 1097\u20131101 (2017).","journal-title":"Am. J. Med. Genet. A"},{"key":"1296_CR55","doi-asserted-by":"publisher","first-page":"103659","DOI":"10.1016\/j.ejmg.2019.04.016","volume":"63","author":"FB Bengur","year":"2020","unstructured":"Bengur, F. B., Ekmekci, C. G., Karaarslan, E., Gunoz, H. & Alanay, Y. p.Ser348Cys mutation in FGFR3 gene leads to \u201cmild ACH\/severe HCH\u201d phenotype. Eur. J. Med. Genet. 63, 103659 (2020).","journal-title":"Eur. J. Med. Genet."},{"key":"1296_CR56","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1002\/ajmg.a.37557","volume":"170","author":"K Hasegawa","year":"2016","unstructured":"Hasegawa, K. et al. A novel mutation p.Ser348Cys in FGFR3 causes achondroplasia. Am. J. Med. Genet. A 170, 1370\u20131372 (2016).","journal-title":"Am. J. Med. Genet. A"},{"key":"1296_CR57","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1093\/labmed\/lmaa116","volume":"52","author":"C Chaudhry","year":"2021","unstructured":"Chaudhry, C. et al. Achondroplasia \u2014 first report from India of a rare FGFR3 gene variant. Lab. Med. 52, 499\u2013502 (2021).","journal-title":"Lab. Med."},{"key":"1296_CR58","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000014157","volume":"98","author":"G Yao","year":"2019","unstructured":"Yao, G., Wang, G., Wang, D. & Su, G. Identification of a novel mutation of FGFR3 gene in a large Chinese pedigree with hypochondroplasia by next-generation sequencing: a case report and brief literature review. Medicine 98, e14157 (2019).","journal-title":"Medicine"},{"key":"1296_CR59","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1002\/ajmg.a.31556","volume":"143A","author":"HG Santos","year":"2007","unstructured":"Santos, H. G., Almeida, M., Fernandes, H. & Wilkie, A. Clinical hypochondroplasia in a family caused by a heterozygous double mutation in FGFR3 encoding GLY380LYS. Am. J. Med. Genet. A 143A, 355\u2013359 (2007).","journal-title":"Am. J. Med. Genet. A"},{"key":"1296_CR60","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1002\/(SICI)1098-1004(1998)11:4<333::AID-HUMU17>3.0.CO;2-J","volume":"11","author":"G Grigelionien\u00e9","year":"1998","unstructured":"Grigelionien\u00e9, G. et al. A novel missense mutation Ile538Val in the fibroblast growth factor receptor 3 in hypochondroplasia. Mutations in brief no. 122. Online. Hum. Mutat. 11, 333 (1998).","journal-title":"Online. Hum. Mutat."},{"key":"1296_CR61","doi-asserted-by":"publisher","first-page":"S62","DOI":"10.1002\/humu.1380110122","volume":"11","author":"PP Deutz-Terlouw","year":"1998","unstructured":"Deutz-Terlouw, P. P., Losekoot, M., Aalfs, C. M., Hennekam, R. C. M. & Bakker, E. Asn540Thr substitution in the fibroblast growth factor receptor 3 tyrosine kinase domain causing hypochondroplasia. Hum. Mutat. 11, S62\u2013S65 (1998).","journal-title":"Hum. Mutat."},{"key":"1296_CR62","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/S0031-3955(16)36192-2","volume":"34","author":"SD Barbour","year":"1987","unstructured":"Barbour, S. D. Acquired immunodeficiency syndrome of childhood. Pediatr. Clin. North. Am. 34, 247\u2013268 (1987).","journal-title":"Pediatr. Clin. North. Am."},{"key":"1296_CR63","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1136\/jmg.37.3.220","volume":"37","author":"G Mortier","year":"2000","unstructured":"Mortier, G. et al. Clinical and radiographic features of a family with hypochondroplasia owing to a novel Asn540Ser mutation in the fibroblast growth factor receptor 3 gene. J. Med. Genet. 37, 220\u2013224 (2000).","journal-title":"J. Med. Genet."},{"key":"1296_CR64","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1002\/ajmg.a.10238","volume":"119A","author":"C Thauvin-Robinet","year":"2003","unstructured":"Thauvin-Robinet, C. et al. Hypochondroplasia and stature within normal limits: another family with an Asn540Ser mutation in the fibroblast growth factor receptor 3 gene. Am. J. Med. Genet. A 119A, 81\u201384 (2003).","journal-title":"Am. J. Med. Genet. A"},{"key":"1296_CR65","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/ng0795-357","volume":"10","author":"GA Bellus","year":"1995","unstructured":"Bellus, G. A. et al. A recurrent mutation in the tyrosine kinase domain of fibroblast growth factor receptor 3 causes hypochondroplasia. Nat. Genet. 10, 357\u2013359 (1995).","journal-title":"Nat. Genet."},{"key":"1296_CR66","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1093\/hmg\/4.11.2097","volume":"4","author":"P Prinos","year":"1995","unstructured":"Prinos, P., Costa, T., Sommer, A., Kilpatrick, M. W. & Tsipouras, P. A common FGFR3 gene mutation in hypochondroplasia. Hum. Mol. Genet. 4, 2097\u20132101 (1995).","journal-title":"Hum. Mol. Genet."},{"key":"1296_CR67","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1159\/000297575","volume":"220","author":"M Blomberg","year":"2010","unstructured":"Blomberg, M., Jeppesen, E. M., Skovby, F. & Benfeldt, E. FGFR3 mutations and the skin: report of a patient with a FGFR3 gene mutation, acanthosis nigricans, hypochondroplasia and hyperinsulinemia and review of the literature. Dermatology 220, 297\u2013305 (2010).","journal-title":"Dermatology"},{"key":"1296_CR68","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1111\/j.1525-1470.2010.01331.x","volume":"27","author":"DR Berk","year":"2010","unstructured":"Berk, D. R. et al. Acanthosis nigricans and hypochondroplasia in a child with a K650Q mutation in FGFR3. Pediatr. Dermatol. 27, 664\u2013666 (2010).","journal-title":"Pediatr. Dermatol."},{"key":"1296_CR69","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1530\/EJE-08-0393","volume":"159","author":"L Castro-Feij\u00f3o","year":"2008","unstructured":"Castro-Feij\u00f3o, L. et al. Hypochondroplasia and acanthosis nigricans: a new syndrome due to the p.Lys650Thr mutation in the fibroblast growth factor receptor 3 gene? Eur. J. Endocrinol. 159, 243\u2013249 (2008).","journal-title":"Eur. J. Endocrinol."},{"key":"1296_CR70","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/pde.13748","volume":"36","author":"L Muguet Guenot","year":"2019","unstructured":"Muguet Guenot, L. et al. Acanthosis nigricans, hypochondroplasia, and FGFR3 mutations: findings with five new patients, and a review of the literature. Pediatr. Dermatol. 36, 242\u2013246 (2019).","journal-title":"Pediatr. Dermatol."},{"key":"1296_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2023.147881","volume":"892","author":"Z Spurn\u00e1","year":"2024","unstructured":"Spurn\u00e1, Z. et al. Clinical-genetic analysis of selected genes involved in the development of the human skeleton in 128 Czech patients with suspected congenital skeletal abnormalities. Gene 892, 147881 (2024).","journal-title":"Gene"},{"key":"1296_CR72","doi-asserted-by":"publisher","first-page":"24252","DOI":"10.18632\/oncotarget.8132","volume":"7","author":"H Patani","year":"2016","unstructured":"Patani, H. et al. Landscape of activating cancer mutations in FGFR kinases and their differential responses to inhibitors in clinical use. Oncotarget 7, 24252\u201324268 (2016).","journal-title":"Oncotarget"},{"key":"1296_CR73","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41439-018-0001-2","volume":"5","author":"I Takahashi","year":"2018","unstructured":"Takahashi, I. et al. A novel S269C mutation in fibroblast growth factor receptor 3 in a Japanese child with hypochondroplasia. Hum. Genome Var. 5, 1 (2018).","journal-title":"Hum. Genome Var."},{"key":"1296_CR74","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/s41431-024-01776-8","volume":"33","author":"P Jacob","year":"2025","unstructured":"Jacob, P. et al. Genetic and allelic heterogeneity in 248 Indians with skeletal dysplasia. Eur. J. Hum. Genet. 33, 607\u2013613 (2025).","journal-title":"Eur. J. Hum. Genet."},{"key":"1296_CR75","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.cca.2013.04.015","volume":"423","author":"H Wang","year":"2013","unstructured":"Wang, H. et al. A novel missense mutation of FGFR3 in a Chinese female and her fetus with hypochondroplasia by next-generation sequencing. Clin. Chim. Acta 423, 62\u201365 (2013).","journal-title":"Clin. Chim. Acta"},{"key":"1296_CR76","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.gene.2017.10.062","volume":"641","author":"J Chen","year":"2018","unstructured":"Chen, J. et al. Identification of a novel mutation in the FGFR3 gene in a Chinese family with hypochondroplasia. Gene 641, 355\u2013360 (2018).","journal-title":"Gene"}],"container-title":["Nature Reviews Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41574-026-01296-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41574-026-01296-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41574-026-01296-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:19:20Z","timestamp":1787242760000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41574-026-01296-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,20]]},"references-count":76,"alternative-id":["1296"],"URL":"https:\/\/doi.org\/10.1038\/s41574-026-01296-z","relation":{},"ISSN":["1759-5029","1759-5037"],"issn-type":[{"value":"1759-5029","type":"print"},{"value":"1759-5037","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,20]]},"assertion":[{"value":"4 August 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This work was supported by an unrestricted educational grant from BioMarin. A.D. has served as a consultant for BioMarin, Ascendis\u00a0Pharma, QED, Novo Nordisk, Pfizer, Sandoz, and Eton Pharmaceuticals and received grant funding from BioMarin and Pfizer. M.S.C. is an investigator for BioMarin trials in achondroplasia and hypochondroplasia, has received consulting fees and payments for honoraria for lectures, presentations, and manuscript writing from BridgeBio Pharma and BioMarin, and has received consulting fees from Tyra and\u00a0BioScientifica. M.S.C. is also an unpaid member of the Drug Medical Committee for a trial in achondroplasia for Ascendis\u00a0Pharma, and holds unpaid leadership or fiduciary roles in the Skeletal Dysplasia Group, Skeletal Dysplasia Management Consortium and the Achondroplasia Network Meeting. J.H.-F. has received grants and contracts for clinical trials from BioMarin, BridgeBio Pharma and Pfizer, has received consulting fees from BioMarin, BridgeBio Pharma, Ascendis\u00a0Pharma, Tyra and Novo Nordisk, has received honoraria for Medscape and BioMarin, and has participated on advisory boards with MCDS-Therapy Clinical Trial (unpaid), BioMarin, and BridgeBio Pharma. S.O.F. has participated in advisory boards and given presentations for BioMarin, Sanofi, Ascendis Pharma, BridgeBio Pharma and Novo Nordisk, honoraria have been paid to his institution, and he is principal investigator in ongoing clinical trials for BridgeBio Pharma and Ascendis Pharma. M.A. has received honoraria for lectures and educational events from BioMarin, Sanofi and AstraZeneca, has received travel support for educational events and conferences from BioMarin, Sanofi and AstraZeneca. S.B., A.C., V.C.-D. and P.K. report no competing interests. V.F. has participated in hypochondroplasia and achondroplasia clinical research at the Garrahan Hospital on BMD with QED. T.K. has received lecture fees from Kyowa Kirin and Novo Nordisk, consulting fees from BioMarin and Kyowa Kirin and grants from BioMarin and Kyowa Kirin. J.L.J. has participated in advisory boards for BioMarin, has received grants and fees for research, and participated in scientific and advisory board meetings for BioMarin and Ascendis\u00a0Pharma, and is a medical consultant for the Brazilian Achondroplasia Patient Organization (ANNABRA). M.M. has received grant support from Pfizer, Novo Nordisk, Merck Serono, and Rhythm Pharmaceuticals; consulting fees and honoraria for lectures, presentations, speaker bureau activities, manuscript writing, or educational events from Pfizer, Novo Nordisk, Sandoz, Merck Serono, Rhythm Pharmaceuticals, Ascendis\u00a0Pharma, and BioMarin; and has participated on a data safety monitoring board\/advisory board for Pfizer. G.M. has received consulting fees and payment for lectures or presentations and financial support for attending meetings from BioMarin, Pfizer and Sanofi. N.N. has received consultancy\/advisory board honoraria from BioMarin, Kyowa Kirin, Ascendis\u00a0Pharma and Teijin, speaking fees from BioMarin, Kyowa Kirin, Teijin and Novo Nordisk, and is a current or prior investigator on trials for BioMarin, Kyowa Kirin, Ascendis\u00a0Pharma, and Teijin. A.C.O. has received grant funding from Alexion, and honoraria from Alexion and BioMarin. K.O. has received fees for lectures and brochure production from BioMarin, and lecture fees from Alexion and Sanofi Japan. S.B.S. has received honoraria for lectures, advisory board participation, and\/or travel support from BioMarin, Ascendis Pharma, and Kyowa Kirin, and has served as an investigator in observational studies and\/or clinical trials for Pfizer, Ascendis Pharma, BioMarin, and QED\/BridgeBio Pharma. R.S. has received honoraria from BioMarin, QED and Ascendis Pharma.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}